Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
18.38
+0.39 (2.17%)
At close: Oct 28, 2025, 4:00 PM EDT
18.51
+0.13 (0.71%)
Pre-market: Oct 29, 2025, 9:07 AM EDT
Avalo Therapeutics Revenue
Avalo Therapeutics had revenue of $441.00K in the twelve months ending June 30, 2025, down -45.35% year-over-year. In the year 2024, Avalo Therapeutics had annual revenue of $441.00K, down -77.08%.
Revenue (ttm)
$441.00K
Revenue Growth
-45.35%
P/S Ratio
548.16
Revenue / Employee
$19,174
Employees
23
Market Cap
241.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 441.00K | -1.48M | -77.08% |
| Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
| Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
| Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
| Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
AVTX News
- 4 weeks ago - Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources - GlobeNewsWire
- 5 weeks ago - Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewsWire
- 2 months ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results - Seeking Alpha
- 2 months ago - Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors - GlobeNewsWire
- 6 months ago - Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 6 months ago - Avalo Therapeutics to Participate in The Citizens Life Sciences Conference - GlobeNewsWire